Koers Biosyent Inc. Toronto S.E.
Aandelen
RX
CA0906901081
Farmaceutische producten
Omzet 2024 * | 35 mln. 25,58 mln. 23,41 mln. | Omzet 2025 * | 38,7 mln. 28,29 mln. 25,89 mln. | Marktkapitalisatie | 116 mln. 84,72 mln. 77,54 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 3,31 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 3 x |
K/w-verhouding 2024 * |
18,2
x | K/w-verhouding 2025 * |
15,9
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 60,64% |
Recentste transcriptie over Biosyent Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 64 | 01-01-96 |
Robert March
DFI | Director of Finance/CFO | - | 10-09-18 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 08-01-18 |
René Goehrum
CEO | Chief Executive Officer | 64 | 01-01-96 |
Peter Lockhard
BRD | Director/Board Member | 60 | 01-06-02 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+55,35% | 815 mld. | |
+32,26% | 597 mld. | |
-0,10% | 377 mld. | |
+15,47% | 319 mld. | |
+13,10% | 310 mld. | |
+16,19% | 247 mld. | |
+14,17% | 228 mld. | |
+16,54% | 180 mld. | |
+4,31% | 170 mld. |